173 related articles for article (PubMed ID: 15053313)
1. Is the mass screening for neuroblastoma ineffective?
Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
[TBL] [Abstract][Full Text] [Related]
2. Mass screening of neuroblastoma in Sapporo City, Japan.
Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
[TBL] [Abstract][Full Text] [Related]
3. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
4. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
Carlsen NL
Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
[TBL] [Abstract][Full Text] [Related]
5. Neuroblastoma screening at one year of age.
Schilling FH; Spix C; Berthold F; Erttmann R; Fehse N; Hero B; Klein G; Sander J; Schwarz K; Treuner J; Zorn U; Michaelis J
N Engl J Med; 2002 Apr; 346(14):1047-53. PubMed ID: 11932471
[TBL] [Abstract][Full Text] [Related]
6. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
8. [Economic evaluation of screening for neuroblastoma].
Lacour A; Chauvin F; Duru G; Philip T
Rev Epidemiol Sante Publique; 1994; 42(1):24-33. PubMed ID: 8134663
[TBL] [Abstract][Full Text] [Related]
9. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
10. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
Takeda T; Shimada M; Iizuka S; Takasugi N
Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
[TBL] [Abstract][Full Text] [Related]
11. A trial to discriminate spontaneous regression from non-regression cases during mass screening for neuroblastoma.
Nishi M; Miyake H; Takeda T; Yonemori H; Hanai J; Kikuchi Y; Takasugi N
Jpn J Clin Oncol; 1994 Oct; 24(5):247-51. PubMed ID: 7967103
[TBL] [Abstract][Full Text] [Related]
12. Lead-time and overdiagnosis estimation in neuroblastoma screening.
Spix C; Michaelis J; Berthold F; Erttmann R; Sander J; Schilling FH
Stat Med; 2003 Sep; 22(18):2877-92. PubMed ID: 12953286
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
[TBL] [Abstract][Full Text] [Related]
14. Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening.
Soderstrom L; Woods WG; Bernstein M; Robison LL; Tuchman M; Lemieux B
J Natl Cancer Inst; 2005 Aug; 97(15):1118-24. PubMed ID: 16077069
[TBL] [Abstract][Full Text] [Related]
15. Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. NB Screening Study Group.
Sawada T; Shikata T; Matsumura T; Kawakatsu H; Sugimoto T
Prog Clin Biol Res; 1994; 385():371-5. PubMed ID: 7972233
[No Abstract] [Full Text] [Related]
16. Poor prognosis neuroblastoma: is screening the answer?
Craft AW; Parker L
Br J Cancer Suppl; 1992 Aug; 18():S96-101. PubMed ID: 1503935
[TBL] [Abstract][Full Text] [Related]
17. Incidence of neuroblastoma after a screening program.
Barrette S; Bernstein ML; Robison LL; Samson Y; Brossard J; Weitzman S; Woods WG
J Clin Oncol; 2007 Nov; 25(31):4929-32. PubMed ID: 17971590
[TBL] [Abstract][Full Text] [Related]
18. [Neuroblastoma in the Auvergne region from 1986 to 1991: epidemiological data].
Gembara P; Dechelotte P; Chazal J; Chauvin F; Chopard P; Goddon R; Goumy P; Masson A; Malpuech G; Deméocq F
Pediatrie; 1993; 48(11):801-4. PubMed ID: 8058441
[TBL] [Abstract][Full Text] [Related]
19. Children may not benefit from neuroblastoma screening at 1 year of age. Updated results of the population based controlled trial in Germany.
Schilling FH; Spix C; Berthold F; Erttmann R; Sander J; Treuner J; Michaelis J
Cancer Lett; 2003 Jul; 197(1-2):19-28. PubMed ID: 12880955
[TBL] [Abstract][Full Text] [Related]
20. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
